Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.

Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.

Merozoite surface protein 1(42) (MSP1(42)) is a leading blood stage malaria vaccine candidate. In order to induce immune responses that cover the major antigenic polymorphisms, FVO and 3D7 recombinant proteins of MSP1(42) were mixed (MSP1(42)-C1). To improve the level of antibody response, MSP1(42)-...

Full description

Bibliographic Details
Main Authors: Ruth D Ellis, Laura B Martin, Donna Shaffer, Carole A Long, Kazutoyo Miura, Michael P Fay, David L Narum, Daming Zhu, Gregory E D Mullen, Siddhartha Mahanty, Louis H Miller, Anna P Durbin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2809736?pdf=render

Internet

http://europepmc.org/articles/PMC2809736?pdf=render

Similar Items